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Malignant germ cell tumours (MGCTs) of childhood are a rare group of neoplasms that comprise many histological subtypes and arise
at numerous different sites. Genomic imbalances have been described in these tumours but, largely because of the paucity of cases
reported in the literature, it is unclear how they relate to abnormalities in adult MGCTs and impact on potential systems for classifying
GCTs. We have used metaphase-based comparative genomic hybridisation to analyse the largest series of paediatric MGCTs
reported to date, representing 34 primary tumours (22 yolk sac tumours (YSTs), 11 germinomatous tumours and one metastatic
embryonal carcinoma) occurring in children from birth to age 16, including 17 ovarian MGCTs. The large dataset enabled us to
undertake statistical analysis, with the aim of identifying associations worthy of further investigation between patterns of genomic
imbalance and clinicopathological parameters. The YSTs showed an increased frequency of 1p- (P¼0.003), 3pþ (P¼0.02), 4q 
(P¼0.07) and 6q  (P¼0.004) compared to germinomatous tumours. Gain of 12p, which is invariably seen in adult MGCTs, was
present in 53% of primary MGCTs of children aged 5–16 and was also observed in four of 14 YSTs affecting children less than 5.
Two of these cases (14% of MGCTs in children less than 5) showed gain of the 12p11 locus considered to be particularly relevant in
adult MGCTs. Gain of 12p showed a significant association with gain of 12q. Conversely, MGCTs without 12p gain displayed a
significantly increased frequency of loss on 16p (P¼0.04), suggesting that this imbalance may contribute to tumour development in
such cases. This data provides new insight into the biology of this under-investigated tumour group and will direct future studies on
the significance of specific genetic abnormalities.
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Germ cell tumours (GCTs) are a complex group of heterogenous
tumours that comprise both benign and malignant histologies.
Children in the UK under 16 years of age are treated on paediatric
childhood cancer treatment schedules, overseen by Children’s
Cancer and Leukaemia Group (CCLG). Teratomas in children,
whether mature or immature, are deemed benign and treated by
surgery alone (Palmer et al, 2003). Chemotherapy is reserved for
malignant histologies and the rare occurrence of immature
teratoma with widespread seeding (typically peritoneal), when it
is used in an attempt to reduce further spread and facilitate
surgery. These treatment schedules are different from those used
in adults, suggesting that GCTs of adult and childhood are likely to
differ biologically.
We are investigating the biology of paediatric malignant germ
cell tumours (MGCTs), a diverse group presumed to have a
common cell of origin, the primordial germ cell. These tumours
occur at several different anatomical sites and, unlike their adult
counterparts, only 50% occur in the gonad. The remainder arise
in various midline or near-midline sites, presumed to be due to
arrested or aberrant migration of the primordial germ cells during
foetal development. There is a bimodal age distribution of
childhood MGCTs. The MGCT seen in infancy is the yolk sac
tumour (YST), which predominantly arises in the testis but does
also occur in alternative sites, for example within sacrococcygeal
teratomas (SCT). By later childhood, adolescence and early
adulthood, MGCTs are seen in a range of sites, including the
ovary, brain and mediastinum, and may be of various histological
types, especially embryonal carcinoma (EC), choriocarcinoma,
YST and germinomatous tumours (including testicular seminoma
and ovarian dysgerminoma).
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genomic imbalance irrespective of the site in which they occur
(Riopel et al, 1998; Perlman et al, 2000; Rickert et al, 2000;
Schneider et al, 2002; Schneider et al, 2006), consistent with the
hypothesis that they arise from the same progenitor cell. Recently,
a new classification system for GCTs was proposed (Oosterhuis
and Looijenga, 2005), dividing GCTs into five types. In this
classification, early childhood tumours (typically under 5 years of
age and almost exclusively teratoma or YST) are referred to as type
I tumours, and separated from the remainder of MGCTs that occur
in the rest of childhood or throughout the majority of adulthood.
Type II tumours represent all histologies except benign ovarian
teratoma (type IV), spermatocytic seminoma (type III) and
hydatidiform moles (type V). This classification was based upon
the epidemiological and biological differences so far determined
between GCT histologies. An important factor in this regard is said
to be the lack in type I tumours of 12p gain (other than gain of
small, predominantly telomeric regions in some cases). In contrast,
gain of 12p is reported to occur in all type II MGCTs (Oosterhuis
and Looijenga, 2005).
Genomic copy number imbalances (CNIs) in MGCTs of
adulthood have been extensively investigated. Gain of 12p, which
is generated by formation of an isochromosome [iso(12p)] in up to
80% of cases of adult testicular GCTs (TGCTs), appears to be a
specific and early cytogenetic event in all histologies in adults
(Korn et al, 1996; Kraggerud et al, 2000; Looijenga et al, 2000).
Additional karyotypic abnormalities in these tumours include
gains on 1, 7, 8, 12, 21, and X, as well as losses on 11, 13 and 18
(Summersgill et al, 1998; van Echten et al, 2002), but none is found
as consistently as 12p gain. In contrast, genomic CNIs in childhood
MGCTs, whether deemed type I or II, have received comparatively
little investigation. There have been several investigations of small
numbers of cases, generally as a component of studies that also
included teratomas. A wide range of CNIs has been described in
childhood MGCTs, including gains on 1q, 2p, 3, 7, 8, 13, 14, 20q,
21, and X, as well as losses on 1p36, 4q, 6q, 11, 13 and 18; but again
none is seen consistently (Mostert et al, 2000; Perlman et al, 2000;
Schneider et al, 2002; van Echten et al, 2002; Schneider et al, 2006).
In all these studies, comparative genomic hybridisation (CGH)
findings were consistent with previous cytogenetic data and with
verification studies based on fluorescent in situ hybridisation.
Metaphase chromosomes have generally been used for CGH and
only limited additional information appears to have been gained
in the analysis of childhood MGCTs by using 1MB CGH arrays
(Veltman et al, 2005).
An important reason why it is not possible to identify with
confidence which CNIs are important in childhood MGCTs is that
data from only 82 samples (where age and CGH profile are
presented) of these heterogenous tumours have been reported to
date. This lack of information has clinical implications. For
example, there is uncertainty concerning whether MGCTs in
adolescents should be regarded as being of adult or childhood type
and which algorithms are required to inform this decision. We
reasoned that a single large study would allow investigation of
CNIs in childhood MGCTs in relation to histology and clinico-
pathological data and enable statistical investigation of associa-
tions between CNIs.
We have therefore used metaphase CGH to identify CNIs worthy
of further investigation in childhood MGCTs. We deliberately
chose cases from patients of 16 and under, in whom paediatric
treatment schedules are applied in the UK. We used a large series
of 34 paediatric MGCTs, representing the entire Children’s Cancer
and Leukaemia Group (CCLG) bank of frozen tumours available at
the time of the study, together with additional unselected cases
made available from European collaboration with Heinrich Heine
University, Du ¨sseldorf. This study therefore represents the most
comprehensive genomic analysis of this tumour group reported to
date. We have identified previously unreported CNI associations of
potential significance in the biology of childhood MGCTs and, in
particular, have observed that gain of 12p (including 12p11) is
reasonably common in YSTs of children under 5.
MATERIALS AND METHODS
Tumour samples
Banked frozen tissue was provided by the CCLG from children 16
years of age or younger. A total of 29 tumours from United
Kingdom were treated on the extracranial GC 8901 (1989–2004)
study, with three additional specimens made available from the
CCLG intracranial germ cell tumour study and two unselected
specimens from German GPOH-MAKEI studies. Following Multi-
centre Research Ethics Committee approval (ref 02/4/071), tumour
material was transported to Cambridge from the banking centres
across the UK and Germany for analysis. In total, 34 tumours were
analysed, each from a different patient. None of the tumours had
been included in previous studies. Thirty-three cases were primary
tumours, while one was a pulmonary metastasis of an EC of the
testis. Nineteen tumours were stage 1, six stage 2, two stage 3 and
seven stage 4. Two children died (one of disease, one unrelated)
and five relapsed (three of whom had stage 1 disease and received
no primary chemotherapy), with follow-up ranging from 12 to 144
months in disease-free cases.
Each case was provided with a histological diagnosis following
CCLG expert panel review. Patient characteristics are shown in
Table 1. All specimens examined in the study initially underwent
frozen section analysis, with independent review by three separate
histopathologists, two of whom are consultant paediatric histo-
pathologists. This process enabled confirmation of the histopatho-
logical diagnosis and the presence of at least 90% tumour cells in
each frozen tissue sample.
DNA isolation
Sections of tumour were homogenised (PolyTron PT2100) in
TRIzol (Invitrogen, Paisley, UK) to preserve nucleic acids.
Following the addition of chloroform, DNA was extracted from
the interphase/organic phase using ethanol precipitation. The
resultant DNA pellets were serially washed with 0.1 M sodium
citrate in 10% ethanol, before resuspension in water (pH 8.4).
CGH microscopy and analysis
CGH was performed as described previously (Alazawi et al, 2004)
but with modifications. Briefly, 50ng of tumour DNA and male
peripheral blood leucocyte reference DNA were amplified and
labelled by two-step degenerate oligonucleotide-primed (DOP)
PCR using 6MW primer (Foster et al, 2005). Test DNA was
labelled with biotin-16-dUTP and reference DNA with digoxigen-
in-11-dUTP (Roche, Lewes, UK). DOP-PCR products were
combined with 5mg Cot DNA (Roche, Lewes, UK) to form probes
before hybridisation with normal male metaphase spreads (Vysis,
Richmond, UK) at 421C for 48h. Following stringency washes,
detection was performed with streptavidin-Cy3 antibody (Amersham
Biosciences, Little Chalfont, UK) and anti-digoxigenin-FITC anti-
body (Roche, Lewes, UK). Chromosomes were counterstained with
DAPI and images captured using an Axioplan II fluorescence
microscope equipped with filter sets for DAPI, FITC and Cy3
(Chroma, Rockingham, VT, USA). Images were acquired using
SmartCapture 2001 software (Digital Scientific, Cambridge, UK)
and analysed using Quips CGH karyotyper (Vysis, Downers Grove,
IL, USA).
At least 10 metaphases were analysed for each sample. The
thresholds used for detection of loss and gain were 0.8 and 1.2,
respectively, based on normal:normal hybridisations using normal
gonadal tissue (data not shown). As the same normal male control
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only autosomal CNIs were assessed.
Statistical analysis
Analysis was carried out in SPSS V13.0. (SPSS Inc, Chicago, IL,
USA) and StatXact V4.0 (Cytel, Cambridge, MA, USA). For each
chromosome arm, gains were compared to nongains (i.e. ‘no
change’ or ‘loss’) and losses were compared to nonlosses (i.e. ‘no
change’ or ‘gain’) using the confidence interval on the difference
of two proportions. These proportions were compared between
different attributes of the dataset, for example YST vs germinoma,
males vs females, etc. The overall aim of the data analysis was to
identify CNI associations worthy of further investigation. In view
of this, although multiple tests were performed, associations were
defined as significant where the P-value was less than or equal to
0.05.
RESULTS
Characteristics of childhood MGCTs analysed
We examined 34 MGCTs from 34 different patients (22 female, 12
male). Of these, 33 cases were primary tumours and one was a
metastasis (Table 1). There were 11 germinomas (eight dysgermi-
nomas, two intracranial germinomas and one arising within an
ovarian teratoma), 22 YSTs (eight ovarian, seven testicular, five
SCT, one intracranial, one vaginal) and one EC (pulmonary
metastasis from a testicular primary). Twenty-four of the primary
tumours were gonadal (17 ovarian, seven testicular) and nine were
extragonadal. There was one potential case of gonadal dysgenesis
(case 24), where the contralateral gonad was considered to be a
streak ovary intraoperatively. Otherwise no tumour included in
this study was from patients diagnosed with gonadal dysgenesis (as
determined by the intraoperative findings and long-term clinical
follow-up). Fourteen MGCTs occurred in children less than 5 years
old at diagnosis. All of these were YSTs, of which seven were
testicular, five arose within a SCT, one was ovarian and one
vaginal. Twenty MGCTs occurred in children 5 years or older, of
which 16 were ovarian, three intracranial and one testicular. These
samples included all 11 germinoma cases. The clinicopathological
features of the cases analysed were largely representative of
childhood MGCTs in general (Palmer et al, 2003; Schneider et al,
2004), other than a relative preponderance of ovarian samples.
Seven tumours represented a single MGCT component within a
teratoma and the samples analysed from these cases were
completely or predominantly (490%) composed of the malignant
element (Table 1).
CNIs in the entire sample set
The number of chromosomes showing CNIs varied from 1 to 24
per tumour (mean 9), with slightly more CNIs per YST (mean 9.5,
range 1–24) than per germinoma (mean 7.1, range 2–18)
(Figure 1), although the difference was not significant (P¼0.32,
Mann–Whitney U test). The EC showed 17 CNIs. The numbers of
CNIs are equivalent to those in previous studies (Summersgill et al,
1998; Kraggerud et al, 2000; Mostert et al, 2000; Schneider et al,
2002; Kildal et al, 2004). Commonly observed CNIs in the entire
Table 1 Clinicopathological data for the 34 MGCTs of childhood analysed
Sample Histology Histology subtype Site Age (years) Gender Stage Outcome EFS
a (months)
1 Germinoma Pure Ovary 12 Female 1 Alive 47
2 Germinoma Pure Ovary 13 Female 3 Alive 46
3 Germinoma Pure Ovary 14 Female 2 Alive 40
4 Germinoma Pure Ovary 10 Female 1 Relapse 16
5 Germinoma Pure Ovary 6 Female 4 Alive 20
6 Germinoma Pure Ovary 12 Female 1 Dead 27
7 Germinoma Pure Ovary 12 Female 1 Alive 15
8 Germinoma Pure Ovary 13 Female 1 Relapse 23
9 Germinoma Pure Brain 16 Male 1 Alive 144
10 Germinoma Pure Brain 10 Female 1 Dead 14
11 Germinoma Within teratoma Ovary 12 Female 2 Alive 36
12 Embryonal carcinoma Pure Metastasis
b 15 Male 4 Relapse 8
13 Yolk sac tumour Pure Testis 1 Male 1 Alive 51
14 Yolk sac tumour Pure Testis 1 Male 1 Alive 92
15 Yolk sac tumour Pure Testis 0 Male 1 Alive 37
16 Yolk sac tumour Pure Testis 4 Male 1 Alive 30
17 Yolk sac tumour Pure Testis 1 Male 1 Alive 14
18 Yolk sac tumour Pure Testis 0 Male 1 Alive 12
19 Yolk sac tumour Pure Testis 2 Male 1 Alive 44
20 Yolk sac tumour Pure Ovary 14 Female 4 Alive 78
21 Yolk sac tumour Pure Ovary 13 Female 2 Alive 58
22 Yolk sac tumour Pure Ovary 12 Female 1 Alive 28
23 Yolk sac tumour Pure Ovary 12 Female 1 Alive 69
24 Yolk sac tumour Pure Ovary
c 9 Female 2 Alive 93
25 Yolk sac tumour Pure Ovary 14 Female 1 Relapse 2
26 Yolk sac tumour Pure Ovary 13 Female 3 Alive 72
27 Yolk sac tumour Within teratoma SCT 2 Female 4 Alive 55
28 Yolk sac tumour Within teratoma SCT 3 Female 4 Alive 21
29 Yolk sac tumour Within teratoma SCT 0 Female 4 Alive 42
30 Yolk sac tumour Within teratoma SCT 1 Male 4 Alive 28
31 Yolk sac tumour Within teratoma SCT 1 Male 1 Alive 54
32 Yolk sac tumour Within teratoma Brain 12 Male 1 Alive 136
33 Yolk sac tumour Pure Ovary 0 Female 2 Relapse 4
34 Yolk sac tumour Pure Vagina 1 Female 2 Alive 43
aEFS – Event-free survival.
bPulmonary metastasis of a testicular primary.
cContralateral streak ovary noted peri-operatively, SCT – sacrococcygeal teratoma.
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(44%), 12p (44%), 12q (32%), 19p (32%), 20q (26%), 21 (29%) and
losses on 13 (26%). The most prevalent abnormality seen by us was
loss on 1p, which was detected in 20 (59%) of all MGCTs and 18
(82%) of YSTs. Less frequently, gains on 2q, 6p, 10q, 11p and 20p
were observed (Figure 1).
YSTs vs germinomas
YSTs were significantly more likely than germinomas to contain
gains on 3p and losses on 1p and 6q, with a borderline significant
increase in the frequency of loss on 4q (P¼0.07) (Figure 2). These
imbalances were more typically seen in YSTs of children less than
5 (in whom the tumours were testicular) than in YSTs of children
greater than 5 (in whom the tumours were typically ovarian).
Germinomas showed borderline significant increases in the
frequency of gain on 12q (P¼0.07) and 19q (P¼0.095), and loss
on 11q (P¼0.095) (Figure 2).
Tumour site, stage and patient age
Of the nine extragonadal primary MGCTs analysed, three were
intracranial, five sacrococcygeal (SCT) and one vaginal. The CNIs
seen in these cases were equivalent to those in gonadal tumours of
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Figure 1 Summary karyograms for all 34 MGCTs analysed. Gains are shown by green bars to the right of each chromosome ideogram and losses as red
bars to the left of each ideogram. Only autosomes are displayed. The numbers above or below the bars refer to individual samples. (A) Summary karyogram
for all 14 MGCTs in children o5 years of age. (B) Summary karyogram for all 20 MGCTs in children aged X5&o16.
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ssimilar histologies, consistent with the notion that these tumours
are likely to have arisen from the same cell of origin, albeit
aberrantly sited in the extragonadal cases. Testicular MGCTs,
regardless of type, were more likely than ovarian MGCTs to have
gain on 3p and loss on 8q. A greater number of CNIs per tumour
was observed with increasing stage (mean CNIs of 9.2 for stage 1
and 11.7 for stage 4), although there was no evidence of an
association between stage and any particular CNI. MGCTs
occurring in children less than 5 years of age were more likely to
contain loss on 1p, 4p, 4q and 6q compared to MGCTs in children
of 5 years or more (Table 2).
Chromosome 12p status
Gain on chromosome 12p, which is invariably found in adult
MGCTs (Korn et al, 1996), was observed in 15 of the 34 (44%)
MGCTs analysed (seven germinomas, seven YSTs and one EC). 12p
gain was more prevalent in the germinomatous tumours than the
YSTs, but not significantly so (64 vs 32%; P¼0.11). 12p gain was
present in four of the 14 YSTs that occurred in children less than
5 years old. The regions of gain in these cases were whole
chromosome 12 (case 27), 12p11-pter (case 16), 12p12-pter (case
34) and 12p13-pter (case 13) (Figure 3). Two of the 14 cases
therefore showed gain at the 12p11 locus typically gained in adult
MGCTs. Gain of 12p was more common in children 5 or over, yet
occurred in only 10 of the 19 (53%) primary MGCTs in this age
group. There was no evidence of a significant difference in the
frequency of 12p gain in primary MGCTs of children aged 5 or
over compared to MGCTs of children under 5 (53 vs 29%;
P¼0.19).
When analysing all cases combined, gain on 12p showed a
significant association with gain of 12q (P¼0.01), but there was no
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Figure 2 Summary of detectable CNIs on each chromosome arm for all 34 paediatric MGCTs analysed. Gains¼green, scored 1; losses¼red, scored  1; both gain and loss¼yellow, scored 2.
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sevidence of a significant association with any other CNI (Table 2).
When considering only the MGCTs showing 12p gain, tumours in
children less than 5 were significantly more likely to show gain on
2p, 3p, 11q and loss on 6q than tumours in children of 5 years or
more (Table 2). In the YSTs (all ages), tumours showing 12p gain
were significantly more likely to show loss of 6q and gain of 12q
compared to tumours without 12p gain (Table 2).
Tumours in which 12p gain was absent were more likely to show
16p loss than samples in which 12p gain was present. This applied
to all cases combined and also to the YSTs alone (P¼0.04 for
both) (Table 2). The smallest region of overlap on 16p in all cases
combined was at 16p12–13.1 (Figure 1).
DISCUSSION
The 34 childhood MGCTs analysed in this study constitute the
largest series so far reported and represents a substantial addition
to the 82 cases published to date (see Table 3, which includes data
from the present study, but excludes published cases without a
CGH profile, cases reported on more than one occasion and cases
where the age of the patient was not stated). We have confirmed
the existence of previously recognised CNIs in MGCTs of
childhood, such as losses on 1p, 4, 6q and 13, as well as gains on
1q, 12p, 20 and 21 (Perlman et al, 2000; Oosterhuis and Looijenga,
2005; Veltman et al, 2005). In addition, the relatively large dataset
in our study has enabled us to undertake statistical investigations
and thereby identify novel associations that may be relevant in the
pathogenesis of childhood MGCTs.
It has previously been reported that gain of 12p is invariably
found in adult TGCTs (Korn et al, 1996), typically as a result of
iso(12p) formation. Similarly, 12p gain is exceedingly common in
adult ovarian MGCTs (Riopel et al, 1998; Kraggerud et al, 2000). In
tumours at both sites gain of 12p11–12 (i.e. proximal 12p) is of
particular importance and there is evidence for a potential role for
genes in this region in the suppression of apoptosis (Zafarana et al,
2002). In contrast, gain of 12p has been inconsistently reported in
childhood MGCTs, with gain of 12p13-pter observed more
frequently than gain of more proximal 12p (Oosterhuis and
Looijenga, 2005). This has therefore formed one of the discrimi-
natory cytogenetic features between adult and paediatric (particu-
larly infantile) MGCTs. Interestingly, there is some evidence that
12p gain (whether 12p11 or whole arm) is less frequent in post-
pubertal childhood MGCTs than in adult MGCTs (Rickert et al,
2000; Schneider et al, 2002) (Table 3), suggesting that adolescent
tumours show biological heterogeneity, which is greater than in
adult MGCTs.
It was reported by Veltman et al (2005) that gain of the whole
12p arm or iso(12p) has not been described in GCTs of neonates
or children under 5 years old. In our series there were four cases
with gain of 12p in children under 5, representing gains of whole
chromosome 12 (case 27), 12p11-pter (case 16), 12p12-pter (case
34) and 12p13-pter (case 13). Furthermore, literature review
indicates that 12p gain (not including isolated 12p13-pter gain) has
been reported in approximately 15% of MGCTs occurring in
children less than 5 years of age, whether analysed by CGH
(Table 3), or kayotyping &/or in situ hybridisation (Table 4).
It therefore appears that while 12p gain is less frequent in
childhood MGCTs than in their adult counterparts, and less
frequent in the very young than in older children, the abnormality
can occur in even very young children, where it may well be of
biological and clinical importance. It has been reported that
12p11.2–12.1 gain is associated with progression from carcinoma
in situ to malignancy in adult TGCTs (Ottesen et al, 2003) and that
a 12p amplicon results in more rapid progression in this setting
(Looijenga et al, 1999). As the literature describes so few paediatric
MGCTs, it is not known whether gain of whole arm 12p, or isolated
12p11–12.1, will confer any prognostic disadvantage in children
Table 2 Summary data for 33 primary MGCTs (22 YSTs & 11 Germinomas), listing those CNIs that show a statistically significant association (Po0.05),
with regard to a particular attribute. In the ‘Comparison’ column the numbers in brackets refer to the number of cases in the compared categories
Comparison Over-representation of CNI CNI P-value Difference (95%CI)
Histology (germinoma vs YST) (11 vs 22) YST 1p  0.003 63.6% [27.0%, 88.1%]
6q  0.004 59.1% [21.9%, 82.9%]
3p+ 0.02 45.5% [7.1%, 72.5%]
Gonadal cases (ovarian vs testicular) (17 vs 7) Testicular tumours 3p+ 0.02 53.8% [8.3%, 91.8%]
8q  0.04 42.9% [0.2%, 84.8%]
Age (o5 vs X5 years) (14 vs 19) Age o5 years old 1p  0.01  43.6% [ 76.2%,  9.1%]
4q  0.02  41.4% [ 73.6%,  6.3%]
4p  0.03  37.6% [ 71.3%,  2.6%]
6q  0.02  43.2% [ 75.8 %,  8.0%]
YST cases only, age (o5 vs X5) (14 vs 8) Age X5 years old 3q+ 0.03 50.0% [6.5%, 87.9%]
12p gain (association with other CNIs) 12p gain present (n¼14) 12q+ 0.01 46.6% [11.9%, 77.7%]
12p gain absent (n¼19) 16p  0.04  36.8% [ 67.9%,  3.2%]
12p gain cases only, age (o5 vs X5) (4 vs 10) Age o5 years old 11q+ 0.01  75.0% [ 99.8%,  15.9%]
6q  0.02  70.0% [ 98.3%,  9.2%]
2p+ 0.04  65.0% [ 99.4%,  3.8%]
3p+ 0.04  65.0% [ 99.4%,  3.8%]
YST cases only, 12p gain (association with other CNIs) 12p gain present (n¼7) 6q  0.009 60.0% [17.5%, 92.4%]
12q+ 0.01 57.1% [11.0%, 91.7%]
12p gain absent (n¼15) 16p  0.04  46.7% [ 81.5%,  3.4%]
n = 31 n = 27
Figure 3 Summary fluorescent ratio profiles for chromosome 12 in two
gonadal YSTs, showing the mean fluorescent ratio profile (blue line) and
95% confidence intervals (yellow lines). The left-hand image is from a pure
YST of the testis in a 4-year-old (sample 16); and the right-hand image is
from a pure YST of the ovary in a 13-year-old (sample 21).
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tin-based chemotherapy schedules. However, it is interesting that
12p gain was seen in both of the childhood MGCT relapses
reported to date (Riopel et al, 1998; Rickert et al, 2000). In a
complimentary manner, the typical cytogenetic changes of YSTs in
infants (loss on 1p, 4q and 6q) were also seen in YSTs of children
over 5 years (always ovarian in this study), but with a reduced
frequency. This is in keeping with published findings in pure
histology YSTs affecting adolescents and adults, irrespective of
tumour site (Speleman et al, 1990; de Bruin et al, 1994; Korn et al,
1996; Mostert et al, 1996; van Echten et al, 1996; Riopel et al, 1998;
Summersgill et al, 1998; Kraggerud et al, 2000; Schneider et al,
2006). These findings suggest that whereas biological differences
may exist between MGCTs of similar histology, distinction based
simply on chronological age may not be appropriate.
We investigated which other CNIs may be important in the
presence or absence of 12p gain in paediatric MGCTs. When
analysing all cases combined, 12p gain was significantly associated
with gain of 12q (P¼0.01). As gain on 12p and 12q may represent
aneusomy for chromosome 12, it would be interesting to
investigate whether cases showing both CNIs have different
clinicopathological associations (e.g. histology, patient age),
compared to MGCTs showing 12p gain without 12q gain. However,
this exercise would require a considerably larger sample size than
was available for the present study. For the tumours showing 12p
gain, those affecting children less than 5 years of age were more
likely to show gain on 2p, 3p, 11q, and loss on 6q, than those
affecting children of 5 or more (in which 12p gain may be of
paramount importance). As all of the children under 5 had YSTs,
this observation may reflect a feature of the tumour type (Table 2).
Table 3 Total number of paediatric (p16 years) MGCTs analysed by CGH reported in the literature to date, with relative frequencies of gain of proximal
12p (i.e. excluding isolated 12p13-pter) by age range
Age o 5 years Age X5 o16 years
Case mix 12p gain Case mix 12p gain
Korn et al (1996) 0 0 1 (1 YST) 1
Riopel et al (1998) 1 (1 mixed) 1 9 (6 DG, 2 Mixed, 1 YST) 8
d
Kraggerud et al (2000) 0 0 3 (1 DG, 2 YST) 2
Mostert et al (2000) 5 (5 YST) 3
a 00
Perlman et al (2000) 16 (16 YST) 1 0 0
Rickert et al (2000) 0 0 6 (3 Germinoma, 2 Mixed, 1 YST) 4
Schneider et al (2002) 9 (9 YST) 0 10 (4 Mixed, 3 YST, 2 CC, 1 EC) 6
Veltman et al (2005) 8 (8 YST) 1
b 3 (1 DG, 1 YST, 1 Mixed) 2
e
Schneider et al (2006) 1 (1 mixed) 0 9 (5 Mixed, 3 Germinoma, 1 YST) 7
f
Present study 14 (14 YST) 3
c 20 (9 DG, 8 YST, 2 Germinoma, 1 EC) 9
g
Total 55 9 (16.4%) 61 39 (63.9%)
Case mix includes yolk sac tumour (YST), dysgerminoma (DG), choriocarcinoma (CC), embryonal carcinoma (EC) and mixed malignant germ cell tumour (mixed).
a12p12–13
gain in all three cases.
b45MB gain, but incomplete gain of 12p without including 12p11 or 12p13-pter.
cIncluding one case showing whole chromosome gain (case 27), and a
further case showing gain of 12p12-pter (case 34).
dHigh copy gain at 12p11 alone in two cases.
eDual gain of 12p13-pter and 12p11 in one case.
fIncluding two cases showing
whole chromosome gain (one with high copy gain of 12p), and one case of high copy gain at 12p12.
gIncluding one case showing gain of 12p12–13 (case 5), and a further case
showing gain of 12p12-pter (case 2).
Table 4 Total number of paediatric (p16 years) MGCTs analysed by conventional cytogenetic techniques reported in the literature to date, with relative
frequencies of iso(12p) by age range
Age o 5 years Age X5 o16 years
Case mix iso(12p) Case mix iso(12p)
Oosterhuis et al (1988) 1 (1 YST) 0 0 0
Speleman et al (1990) 0 0 1 (1 Mixed) 1
Shen et al (1990) 0 0 1 (1 Mixed) 0 (but 4 copies of chromosome 12)
Albrecht et al (1993) 0 0 1 (1 Germinoma) 0 (but extra 12p material)
de Bruin et al (1994) 0 0 1 (1 Mixed) 1
Perlman et al (1994) 6 (6 YST) 0 0 0
Stock et al (1994) 6 (2 EC, 2 YST, 2 Mixed) 1 5 (2 DG, 1 Mixed, 2 SE) 1
Jenderny et al (1995) 4 (4 YST) 4
a 2 (2 YST) 1
a
Stock et al (1995) 8 (6 YST, 2 EC) 1 5 (2 DG, 2 Mixed, 1 EC) 2
Sainati et al (1996) 1 (1 EC) 0 0 0
Lemos et al (1998) 1 (1 Geminoma) 0 0 0
Losi et al. (1994) 0 0 1 (1 Mixed) 1
Bussey et al (1999) 21 (11 YST, 7 Mixed, 3 UK) 0 23 (16 Mixed, 3 YST, 2 UK, 1
Germinoma, 1 Malignant teratoma)
2+2 other 12p structural
abnormalities
Okada et al (2002) 0 0 10 (6 Germinoma, 3 Mixed, 1 YST) 2
Van Ecten et al (2002) 3 (3 YST) 0 0 0
Poulos et al (2006) 1 (1 Mixed) 1 2 (2 Mixed) 2
Total 52 7 (13.5%) 52 13 (25%)+4 others
Case mix includes mixed malignant germ cell tumour (mixed), yolk sac tumour (YST), embryonal carcinoma (EC), dysgerminoma (DG), seminoma (SE) and unknown germ cell
tumour (UK).
aGain of chromosome 12 by in situ hybridisation – iso(12p) status unclear, but one case in each age range almost certainly iso(12p).
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MGCTs of childhood, notably YSTs (Rickert et al, 2000; Schneider
et al, 2002), but the association with 12p gain may be particularly
relevant.
In childhood MGCTs where 12p gain is absent, it is likely that
other CNIs are of fundamental significance. Past work has largely
focused on the possibility that tumour suppressor genes exist on
1p or 6q, especially in infantile YSTs (Perlman et al, 2000; Hu et al,
2001), although no candidate genes have yet been identified. In our
study, we discovered that in the absence of 12p gain the most
significant abnormality is loss of 16p (P¼0.04), irrespective of
histology. This raises the possibility that loss of one or more
tumour suppressor genes on 16p, particularly at the smallest
region of overlap of 16p12–13.1, may be an important event in
these tumours. Since many statistical tests were carried out in our
analysis, it will be important first to confirm the new associations
that we have discovered in an independent sample set. Never-
theless, the identification in our study of abnormalities reported by
other groups lends credence to the novel associations that we have
identified.
Recently, a new classification system has been proposed that
separates GCTs into five types (Oosterhuis and Looijenga, 2005),
where the most important discrimination in paediatric cases is
between type I and II tumours. The discrimination is essentially
age related, with the transition at 4–5 years, since it is rare to have
dysgerminoma below this age, or testicular tumours above this
age until the onset of puberty. Cytogenetically, malignant type I
tumours (typically testicular YSTs in boys under 5) are reported
to show gain on 1q, 12p13 and 20q, as well as loss on 1p, 4
and 6q. Type II tumours (of any histological type other than
mature teratoma) have gain on chromosome 7, 8, 12p, 21 and X,
with loss of 1p, 11, 13 and 18 (Kraggerud et al, 2000; Rickert et al,
2000; Oosterhuis and Looijenga, 2005). Our study confirms that
loss on 1p, 4 and 6q are strongly associated with MGCTs
(invariably YSTs) of children under the age of 5 years (Table 2),
and therefore putative type I tumours. We also observed an
increase of borderline significance in the frequency of gain on 3p
(P¼0.06) in the tumours occurring in children under 5, which has
been previously described in this age group in smaller studies
(Mostert et al, 2000; Schneider et al, 2002; Veltman et al, 2005).
However, we do not confirm that gain of 12p (specifically 12p11) is
restricted to children aged 5 or over, nor to germinomatous
tumours.
Furthermore, not all MGCTs in children 5 and over in our study
followed the proposed type II cytogenetic profile. In comparison to
the 14 MGCTs in children under 5, the 19 primary MGCTs in
children of 5 or over showed minor increases in the frequency of
gain on 2q, 3q, 12 and loss on 11q only, with none of these
differences attaining even borderline statistical significance (data
not shown). Moreover, loss on 11p or 18 was not seen in any of the
19 primary tumours of children aged 5 or more and gain of 12p
was seen in only 10 cases (53%). It should be noted that 16 of the
20 MGCTs of children aged 5 and over were ovarian, cases that are
under-represented in the published literature.
Our findings suggest that due to the relative lack of childhood
MGCTs analysed to date, the proposed classification system may
rely too heavily on data from adult TGCTs. This view would be
concordant with known clinical outcome data, which indicates
that childhood MGCTs can be treated differently to their adult
counterparts without adverse outcomes well into adolescence
(Mann et al, 2000). Where the biological cut-off between childhood
and adult MGCTs occurs, and what biology underpins this, has still
to be elucidated. However, any new classification of GCTs needs to
take these issues into account and provide robust epidemiological,
biological and therapeutically beneficial information. This should
be possible by integrating data produced for adult and childhood
MGCTs but needs to take account of transcriptional profiles, as
well as the increasing volume of available genomic and epigenetic
information.
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